Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith M Regan

Showing results (121-130 of 243) with videos related to

Pageof 25
Sort By:
The Lancet. Oncology|October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upMeredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
JAMA Oncology|June 15, 2018
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical TrialStephen J Luen, Rebecca Asher, Chee Khoon Lee, et al.
Breast Cancer Research : BCR|November 7, 2012
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXAlan S Coates, Ewan K A Millar, Sandra A O'Toole, et al.
Plos One|June 7, 2013
Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune responseRinath M Jeselsohn, Lillian Werner, Meredith M Regan, et al.
NPJ Breast Cancer|February 7, 2020
DNA methylation markers predict recurrence-free interval in triple-negative breast cancerMary Jo Fackler, Soonweng Cho, Leslie Cope, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 TrialOtto Metzger Filho, Anita Giobbie-Hurder, Elizabeth Mallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid TumorsMartine J Piccart, Florentine S Hilbers, Judith M Bliss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFTOlivia Pagani, Prudence A Francis, Gini F Fleming, et al.
Breast Cancer Research and Treatment|July 4, 2016
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00Giancarlo Pruneri, Kathryn P Gray, Andrea Vingiani, et al.
Breast Cancer Research and Treatment|March 29, 2018
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00Elisabetta Munzone, Kathryn P Gray, Caterina Fumagalli, et al.
Pageof 25

Showing results (121-130 of 243) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upMeredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
JAMA Oncology|June 15, 2018
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical TrialStephen J Luen, Rebecca Asher, Chee Khoon Lee, et al.
Breast Cancer Research : BCR|November 7, 2012
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXAlan S Coates, Ewan K A Millar, Sandra A O'Toole, et al.
Plos One|June 7, 2013
Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune responseRinath M Jeselsohn, Lillian Werner, Meredith M Regan, et al.
NPJ Breast Cancer|February 7, 2020
DNA methylation markers predict recurrence-free interval in triple-negative breast cancerMary Jo Fackler, Soonweng Cho, Leslie Cope, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 TrialOtto Metzger Filho, Anita Giobbie-Hurder, Elizabeth Mallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid TumorsMartine J Piccart, Florentine S Hilbers, Judith M Bliss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFTOlivia Pagani, Prudence A Francis, Gini F Fleming, et al.
Breast Cancer Research and Treatment|July 4, 2016
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00Giancarlo Pruneri, Kathryn P Gray, Andrea Vingiani, et al.
Breast Cancer Research and Treatment|March 29, 2018
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00Elisabetta Munzone, Kathryn P Gray, Caterina Fumagalli, et al.
Pageof 25